(Q40520293)

21 September 2017

1 reference

title

Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal (English)

1 reference

21 September 2017

A Capucci

1

1 reference

21 September 2017

G Boriani

series ordinal

2

1 reference

21 September 2017

publication date

1 January 1995

1 reference

21 September 2017

1 reference

21 September 2017

volume

12

1 reference

21 September 2017

issue

1

1 reference

21 September 2017

page(s)

55-72

1 reference

Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: Electrophysiologic effects and results of programmed ventricular stimulation

21 September 2017

cites work

1 reference

12 December 2020

Effect of pH on the myocardial uptake and pharmacodynamics of propafenone in the isolated rabbit heart.

1 reference

12 December 2020

Genetically determined variability in acetylation and oxidation. Therapeutic implications

1 reference

12 December 2020

Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias

1 reference

12 December 2020

Propafenone: a promising new antiarrhythmic agent

1 reference

12 December 2020

Beta-blocking effect of propafenone based on spectral analysis of heart rate variability

1 reference

12 December 2020

Oral propafenone therapy for children with arrhythmias: efficacy and adverse effects in midterm follow-up

1 reference

12 December 2020

The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction

1 reference

12 December 2020

The importance of pharmacokinetics and pharmacodynamics in the clinical evaluation of antiarrhythmic drugs

1 reference

12 December 2020

Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

1 reference

12 December 2020

Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy

1 reference

12 December 2020

Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies

1 reference

12 December 2020

Metabolite cumulation during chronic propafenone dosing in arrhythmia.

1 reference

12 December 2020

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

1 reference

12 December 2020

Safety and toxicity of antiarrhythmic drug therapy: benefit versus risk

1 reference

12 December 2020

Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia

1 reference

12 December 2020

Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway

1 reference

12 December 2020

The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation

1 reference

12 December 2020

Effects of propafenone on ventricular arrhythmias: double-blind, parallel, randomized, placebo-controlled dose-ranging study

1 reference

12 December 2020

Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.

1 reference

12 December 2020

Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Pa

1 reference

12 December 2020

Double-blind placebo-controlled evaluation of propafenone in suppressing ventricular ectopic activity

1 reference

12 December 2020

Clinical experience with propafenone for cardiac arrhythmias in the young

1 reference

12 December 2020

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences

1 reference

12 December 2020

Effect of antiarrhythmic drugs on mortality after myocardial infarction

1 reference

12 December 2020

Low frequency of slow debrisoquine hydroxylation in a native Chinese population

1 reference

12 December 2020

Propafenone in the treatment of chronic ventricular arrhythmias in a pregnant patient

1 reference

12 December 2020

Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial

1 reference

12 December 2020

Propafenone, a review of its profile

1 reference

12 December 2020

Ethnic differences in drug metabolism

1 reference

12 December 2020

Propafenone for prevention of recurrent atrial fibrillation

1 reference

12 December 2020

Intravenous administration of propafenone

1 reference

12 December 2020

Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia

1 reference

12 December 2020

The multiple modes of action of propafenone

1 reference

12 December 2020

Antiarrhythmic efficacy of propafenone: evaluation of effective plasma levels following single and multiple doses

1 reference

12 December 2020

Therapeutic efficacy and safety of oral propafenone for atrial fibrillation

1 reference

12 December 2020

Intravenous propafenone for termination of reentrant supraventricular tachycardia. A placebo-controlled, randomized, double-blind, crossover study

1 reference

12 December 2020

Atrial flutter in patients treated for atrial fibrillation with propafenone

1 reference

12 December 2020

Comparison of the pharmacodynamic effects of intravenous and oral propafenone

1 reference

12 December 2020

Determination of oxidative phenotype in a sample population and correlation with the pharmacokinetics of propafenone

1 reference

12 December 2020

Electrophysiologic effects of propafenone on canine ischemic cardiac cells

1 reference

12 December 2020

Propafenone: a new agent for ventricular arrhythmia

1 reference

12 December 2020

Propafenone for paroxysmal atrial fibrillation

1 reference

12 December 2020

ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg

1 reference

12 December 2020

Risks and benefits of antiarrhythmic therapy

1 reference

12 December 2020

Atrial automatic tachycardia in children

1 reference

12 December 2020

A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators

1 reference

12 December 2020

Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset

1 reference

12 December 2020

Clinical pharmacology of propafenone

1 reference

12 December 2020

Differential analysis of the frequency-dependent effects of class 1 antiarrhythmic drugs according to periodical ligand binding: implications for antiarrhythmic and proarrhythmic efficacy

1 reference

12 December 2020

Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians

1 reference

12 December 2020

The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm

1 reference

12 December 2020

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

1 reference

12 December 2020

Oxidation phenotype--a major determinant of metoprolol metabolism and response

1 reference

12 December 2020

Five-year follow-up of 589 patients treated with amiodarone

1 reference

12 December 2020

A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm

1 reference

12 December 2020

1 reference

12 December 2020

Myocardial uptake kinetics and pharmacodynamics of propafenone in the isolated perfused rabbit heart

1 reference

12 December 2020

Propafenone for malignant ventricular arrhythmia: an analysis of the literature

1 reference

12 December 2020

[Pharmacologic cardioversion with propafenone of stable atrial fibrillation of recent onset]

1 reference

12 December 2020

Debrisoquine oxidation in an Australian population

1 reference

12 December 2020

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

1 reference

12 December 2020

Intrauterine therapy of fetal tachyarrhythmias: intraperitoneal administration of antiarrhythmic drugs to the fetus in fetal tachyarrhythmias with severe hydrops fetalis

1 reference

12 December 2020

QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards

1 reference

12 December 2020

Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter

1 reference

12 December 2020

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

12 December 2020

The metabolic fate of 2H-labelled propafenone in man

1 reference

12 December 2020

The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology

1 reference

12 December 2020

Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up

1 reference

12 December 2020

A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarizations: A meta-analysis

1 reference

12 December 2020

The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population

1 reference

12 December 2020

Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs

1 reference

12 December 2020

Wolff-Parkinson-White syndrome. Identification and management

1 reference

12 December 2020

Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias

1 reference

12 December 2020

Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients treated for ventricular tachycardia or fibrillation

1 reference

12 December 2020

Usefulness of intravenous propafenone for control of postoperative junctional ectopic tachycardia

1 reference

12 December 2020

Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.

1 reference

12 December 2020

Drugs, surgery, cardioverter defibrillator: a decision based on the clinical problem

1 reference

12 December 2020

Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide

1 reference

12 December 2020

A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians

1 reference

12 December 2020

Stereoselective disposition and pharmacologic activity of propafenone enantiomers

1 reference

12 December 2020

Amiodarone for refractory atrial fibrillation

1 reference

12 December 2020

A study of the debrisoquine hydroxylation polymorphism in a Nigerian population

1 reference

12 December 2020

The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology

1 reference

12 December 2020

Are different pharmacokinetic properties of lidocaine versus propafenone in normal as compared to ischemic myocardium responsible for different electrophysiologic effects which help preventing arrhythmias?

1 reference

12 December 2020

Side effects from amiodarone

1 reference

12 December 2020

Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery

1 reference

12 December 2020

A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs

1 reference

12 December 2020

Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias

1 reference

12 December 2020

Guidelines for the use of implantable cardioverter defibrillators. A Task Force of the Working Groups on Cardiac Arrhythmias and Cardiac Pacing of the European Society of Cardiology

1 reference

12 December 2020

Antiarrhythmic treatment of atrioventricular tachycardias

1 reference

12 December 2020

Investigations on the pharmacokinetics of propafenone in man

1 reference

12 December 2020

The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone

1 reference

12 December 2020

Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers

1 reference

12 December 2020

Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone

1 reference

12 December 2020

10.2165/00002018-199512010-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

21 September 2017

1050744732

0 references

1 reference